Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Robert J. Decker, Vice President and Corporate Controller at Johnson & Johnson (NYSE:JNJ), recently sold a substantial portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Decker disposed of 6,999 shares of common stock on February 25, 2025, at prices ranging between $165.88 and $165.895, culminating in a total transaction value of approximately $1.16 million.
In a separate transaction on the same day, Decker exercised options to acquire 6,999 shares at a price of $101.87 per share, totaling $712,988. Following these transactions, Decker holds 21,001 shares directly, with additional shares held indirectly through a 401(k) and ESOP plans. According to InvestingPro analysis, JNJ’s RSI indicates overbought territory, which may explain the timing of this insider sale.
These transactions are part of routine portfolio management and do not necessarily indicate any specific outlook on the company’s future performance. Johnson & Johnson remains a key player in the pharmaceutical preparations sector, continuing to draw investor attention.
In other recent news, Johnson & Johnson has completed a multi-billion euro public offering of notes, raising significant capital to be used for general corporate purposes. The notes, which range in maturity from 2029 to 2055, were part of an SEC filing and involved major underwriters such as Citigroup (NYSE:C) Global Markets Limited and Goldman Sachs & Co. LLC. Additionally, the company has successfully issued $5 billion in new notes with varying maturity dates and interest rates, as part of its capital management strategy. S&P Global Ratings assigned an ’AAA’ rating to these new notes but placed them on CreditWatch Negative, partly due to Johnson & Johnson’s announced acquisition of Intra-Cellular Therapies (NASDAQ:ITCI) Inc., valued at approximately $14.6 billion.
In the healthcare sector, Johnson & Johnson’s stock is noted by BTIG’s Jonathan Krinsky as nearing a breakout, reflecting positive momentum in the sector. Meanwhile, Johnson & Johnson announced promising results for its drug TREMFYA® in treating ulcerative colitis, with the Phase 3 ASTRO study showing significant improvements over placebo. Applications for approval of TREMFYA® for both ulcerative colitis and Crohn’s disease have been submitted in Europe, with the FDA already granting approval for the drug’s intravenous induction regimen. These recent developments highlight Johnson & Johnson’s strategic financial maneuvers and advancements in its pharmaceutical offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.